Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies

Potential First-In-Class Wnt Agonist

Executive Summary

Led by the duo who brought the first anti-VEGF drug to market, EyeBio aims to develop the next breakthrough eye therapy via a novel tri-specific antibody.

You may also be interested in...

Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs

Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.

Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head

Roche’s next-generation eye drug Vabysmo has enjoyed a strong launch, but new head-to-head trials in a potential new indication, retinal vein occlusion, appear to offers up few advantages over market leader Eylea.

Exkivity Withdrawal Is Blow To Takeda’s Oncology Ambitions

The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts